Exciva

About Exciva

Exciva GmbH, established in 2016 in Heidelberg, Germany, is a privately held biotech company focused on developing clinical stage therapeutics for neuropsychiatric indications, particularly targeting neuropsychiatric symptoms of dementia such as agitation and aggression in Alzheimer's disease. Their mission is to improve the quality of life and independence of patients, reduce caregiver distress, and transform dementia care worldwide through cutting-edge research and clinical trials.

Products & Services

EXV-802:Lead program for the treatment of agitation in dementia associated with Alzheimer's disease, which received Fast Track designation from the US FDA.

Therapies for Neuropsychiatric Symptoms of Dementia:Focused on developing groundbreaking therapies to address symptoms like agitation and aggression in Alzheimer's disease dementia.

Specialties

Neuropsychiatric therapeutics Alzheimer's disease treatment Agitation and aggression in dementia Clinical stage drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 55000000 MR: - FA: EUR 51 million FAN: 55000000	D: 2026-01-20 FD: 2026-01-20	8 investors

Series B Latest

2026-01-20

$55.0M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

François Conquet

CEO

D

Duc Tran

COO

N

Nadine Knowles

COO

H

Hans Moebius

Co-founder and CMO

F

Fiona Hattey

Head of Clinical Operations

A

Anton Bespalov

Co-founder and CSO

View 17 more team members with Pro

Unlock Full Team Directory

Recent News

Exciva Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised